Our Medicines That Are Helping Patients Today
Together with our healthcare partners, Daiichi Sankyo is helping patients live healthier lives. Our comprehensive portfolio offers a wide range of treatments for patients in a number of disease categories including hypertension, heart disease, diabetes and hyperlipidemia/atherosclerosis.
From the discovery of epinephrine (also known as adrenaline) in 1889, to the development of the statin class of lipid-lowering agents and the first glitazone, which revolutionized long-term control of type 2 diabetes, our history of innovation continues to define our vision and purpose. With our scientific curiosity, willingness to examine new ideas and pairing of existing information with novel concepts, we create medicines as well as new methods of drug discovery and delivery.
The products below, which are currently marketed in the U.S., are the result.